小夏
Lv4
410 积分
2022-11-14 加入
-
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
1天前
已完结
-
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
1天前
已完结
-
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics
1天前
已完结
-
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
1天前
已完结
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4天前
已完结
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4天前
已完结
-
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis
9天前
已完结
-
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
1个月前
已完结
-
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
1个月前
已完结
-
Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen–Based Therapies for Prostate Cancer
1个月前
已完结